Advertisement
Bilastine is a new highly selective H1 antihistamine for once daily oraladministration. Allergic rhinitis prevalence in Europe is approximately 23%and many patients are under-diagnosed and under-treated. Bilastine has beenassessed in multiple human trials involving 4,000 patients, including twopivotal Phase III trials.
Advertisement
The agreement includes milestone payments and royalties of 10-15% ofannual sales in the licensed territories, incorporating the 27 EU memberstates and 24 additional countries in Eastern Europe, Scandinavia, CentralAsia and the Mediterranean region. The Menarini Group is a privately heldcompany headquartered in Florence Italy with 12,000 employees and estimated2007 turnover of euro 2,500M.
About Burrill Merchant Banking
Burrill Merchant Banking assists life science companies to identify,negotiate and close strategic transactions. Service lines include:
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leaderin life sciences with activities in Private Equity, Venture Capital, MerchantBanking and Media. The Burrill family of venture capital funds has over $950million under management and its merchant banking business is one of theindustry leaders in life sciences transactions. The company's 60 personscientific and business team, supported by its 40-person Advisory Boards, thestrategic and financial network of its limited partners, and the closerelationships developed with numerous life sciences companies and management,provide Burrill with unparalleled access and insight.
Burrill is the creator, sponsor and facilitator of over a dozen leadingindustry conferences worldwide and publishes a wide range of bio-intelligencereports including: The Personalized Medicine Report, The Stem Cell Report, andperiodic newsletters covering Canada, China, Europe, India, Japan andPartnering/M&A. In association with the California Healthcare Institute,Burrill publishes The Journal of Life Sciences -- a bimonthly magazine.Burrill's flagship publication is its annual "State of the Industry" report,the most recent 21st Edition being Biotech 2007: Life Sciences - A GlobalTransformation. The 22nd Edition is entitled Biotech 2008: Life Sciences - A20/20 Vision to 2020, available 1Q '08. These publications provide the latestinsight, intelligence and information on the life sciences industry.http://www.burrillandco.com.-- Mergers & Acquisitions -- Strategic Partnering from preclinical research to product development and commercialization -- Spin-Outs and Divestitures -- Financing (Private Placements) -- Advisory Services to define the role of transactions in achieving strategic objectives
SOURCE Burrill Merchant Banking
